Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jul 16, 2018
-- Sunil Gupta, MD, named Vice President Regulatory & Pharmacovigilance -- Anna Wijatyk, MD, named Vice President Clinical Development LEXINGTON, Mass., July 16, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of
Jun 20, 2018
LEXINGTON, Mass., June 20, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1  invites investors and the general public to attend its Annual Meeting of Stockholders to begin
May 17, 2018
- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass., May 17 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a
Mar 29, 2018
LEXINGTON, Mass., March 29, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare
Nov 15, 2017
LEXINGTON, Mass., Nov. 15, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license
Nov 08, 2017
LEXINGTON, Mass., Nov. 8, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater,